Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
2.090
-0.070 (-3.24%)
Nov 22, 2024, 4:00 PM EST - Market closed
Lexaria Bioscience Employees
Lexaria Bioscience had 5 employees as of August 31, 2023. The number of employees decreased by 2 or -28.57% compared to the previous year.
Employees
5
Change (1Y)
-2
Growth (1Y)
-28.57%
Revenue / Employee
$82,204
Profits / Employee
-$969,975
Market Cap
36.48M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Aug 31, 2023 | 5 | -2 | -28.57% |
| Aug 31, 2022 | 7 | 1 | 16.67% |
| Aug 31, 2021 | 6 | 2 | 50.00% |
| Aug 31, 2020 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| RAPT Therapeutics | 131 |
| Barinthus Biotherapeutics | 130 |
| Adagio Medical Holdings | 85 |
| Lumos Pharma | 33 |
| Elevation Oncology | 29 |
| Reviva Pharmaceuticals Holdings | 15 |
| Intensity Therapeutics | 7 |
| Anebulo Pharmaceuticals | 3 |
LEXX News
- 3 days ago - ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study - Accesswire
- 9 days ago - Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study - Accesswire
- 10 days ago - Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss - Accesswire
- 16 days ago - Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments - Accesswire
- 4 weeks ago - Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study - Accesswire
- 4 weeks ago - Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study - Accesswire
- 5 weeks ago - Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Accesswire
- 5 weeks ago - Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Accesswire